UPDATED 7:54 AM PT – Monday, September 27, 2021
Pfizer is moving forward with efforts in making children eligible for the COVID-19 vaccine. The CEO of the pharmaceutical and biotechnology corporation, Alber Bourla, said they are prepared to begin producing the vaccine for children immediately after data is submitted and approved by the FDA.
During an interview on Sunday, company Bourla said he believes they are going to submit data for children ages five through 11 soon. He added, it’s a question of days not weeks. Bourla then noted the FDA will review the data once submitted and come to the conclusion whether to approve the shot.
“If they approve it, we will be ready with our manufacturing to provide this new formulation of the vaccine because the vaccine that the kids will receive, which is five to 11, is a different formulation,” explained the CEO. “It’s one-third of the dose given to the rest of the population.”
Today, we shared positive topline results from the pivotal trial of our COVID-19 vaccine in children 5 to 11 years of age: https://t.co/jQrvb6MZ6w
This is exciting news for families.
— AlbertBourla (@AlbertBourla) September 20, 2021
Although he was asked when or if americans can expect to return to their pre-pandemic lives. he claimed the coronavirus pandemic will not end without a catch.
This comes as the CEO of Moderna predicted last week that by the second half of 2022, mandates won’t be needed and the unvaccinated will have natural immunity.
The Pfizer chairman warned, however, yearly coronavirus revaccination is the most likely scenario moving forward.
“The most likely scenario for me, it is because the virus has spread all over the world, that we will continue seeing new variants that are coming out,” Bourla stated. “And also we will have vaccines that will last at least a year. I think the most likely scenario is annual revaccinations, but we need to wait and see the data.”